New drug aims to regrow hair in severe baldness disorder

NCT ID NCT06340360

Ongoing Disease control Sponsor: Nektar Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests an experimental drug called rezpegaldesleukin in 94 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Participants receive either the drug or a placebo for 36 weeks, with an optional extension. The main goal is to measure hair regrowth using a standard scalp scoring system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA

Contacts and locations

Locations

Nektar Investigative Site

Northridge, California, 91324, United States
Nektar Investigative Site

Atlanta, Georgia, 30331, United States
Nektar Investigative Site

Gurnee, Illinois, 60031, United States
Nektar Investigative Site

Indianapolis, Indiana, 46202, United States
Nektar Investigative Site

Clinton Township, Michigan, 48038, United States
Nektar Investigative Site

Portsmouth, New Hampshire, 03801, United States
Nektar Investigative Site

New York, New York, 10075, United States
Nektar Investigative Site

Camp Hill, Pennsylvania, 17011, United States
Nektar Investigative Site

Frisco, Texas, 75034, United States
Nektar Investigative Site

Pflugerville, Texas, 78660, United States
Nektar Investigative Site

Surrey, British Columbia, V3V 0C6, Canada
Nektar Investigative Site

Markham, Ontario, L3P 1X3, Canada
Nektar Investigative Site

Oakville, Ontario, L6J 7W5, Canada
Nektar Investigative Site

Richmond Hill, Ontario, L4B 1A5, Canada
Nektar Investigative Site

Sherbrooke, Quebec, J1G 1X9, Canada
Nektar Investigative Site

Wroclaw, Lower Silesian Voivodeship, 50-450, Poland
Nektar Investigative Site

Wroclaw, Lower Silesian Voivodeship, 50-566, Poland
Nektar Investigative Site

Wroclaw, Lower Silesian Voivodeship, 51-685, Poland
Nektar Investigative Site

Nowa Sól, Lubusz Voivodeship, 67-100, Poland
Nektar Investigative Site

Warsaw, Masovian Voivodeship, 02-482, Poland
Nektar Investigative Site

Warsaw, Masovian Voivodeship, 02-953, Poland
Nektar Investigative Site

Gdansk, Pomeranian Voivodeship, 80-546, Poland
Nektar Investigative Site

Katowice, Silesian Voivodeship, 40-611, Poland
Nektar Investigative Site

Sosnowiec, Silesian Voivodeship, 41-200, Poland
Nektar Investigative Site

Olsztyn, Warmian-Masurian Voivodeship, 10-229, Poland
Nektar Investigative Site

Szczecin, West Pomeranian Voivodeship, 71-500, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.